Data from the phase 3 ENVISION trial demonstrate the potential of UGN-102 as an effective and durable nonsurgical treatment for patients with low-grade, intermediate-risk non–muscle-invasive bladder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback